Skip to content

Development Of a Virtual Stress Inoculation Training (SIT) Platform and Mobile Health App

Development Of a Virtual Stress Inoculation Training (SIT) Platform and Mobile Health App

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06494319
Enrollment
20
Registered
2024-07-10
Start date
2024-05-28
Completion date
2025-06-30
Last updated
2024-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PTSD, Trauma and Stressor Related Disorders, Traumatic Brain Injury

Keywords

veteran, Post Traumatic Stress Disorder (PTSD), Traumatic Brain Injury, Military

Brief summary

The purpose of this study is to demonstrate the feasibility and utility of SIT delivered asynchronously (self-paced) via fully virtual platform with and without the aid of a mobile health application and to determine initial change over baseline in terms of reduction in PTSD symptoms and improvement in resiliency in participants receiving the virtual SIT prototype, using Linear Mixed Models (LMMs),

Interventions

BEHAVIORALStress NAVIGATOR (Mobile Health Application)

Participants will be prompted to complete their assessments each week (or upon completion of each session) via the Stress NAVIGATOR mobile health app

BEHAVIORALSIT NAVIGATOR

Participants will complete 11 self-paced virtual SIT sessions in the SIT-NAVIGATOR classroom. Participants will be asked to complete at least one session per week, in a minimum of 12 weeks and a maximum of 14 weeks.

Sponsors

The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The first 10 participants will do the treatment via the canvas classroom virtually and participate in user experience interviews to improve the quality of the treatment and improve the user experience.Next, the second group of 10 participants will do the treatment with the canvas classroom aided by a mobile health application.These participants will also participate in user experience interviews to improve the quality of the treatment and improve the user experience.

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* US Military Veterans / Service Members * diagnosis of PTSD as measured by a Posttraumatic Symptom Checklist for DSM-5 (PCL-5) score of \>33 * history of combat trauma and/or military service in an imminent danger pay area * be fluent in English. * be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol. * have access to a SmartPhone or tablet to utilize the mobile health app and/OR access the virtual classroom. * agree to undergo psychometric testing and participate in ongoing assessments throughout the study duration. * be willing to comply with all study procedures, able to complete all assessments independently, and available for the duration of the study.

Exclusion criteria

* Active suicidal ideation as assessed by the Investigator at screening or as identified during the study. * Clinically significant history of psychotic disorder, bipolar spectrum disorder, or neurodegenerative disease/dementia as assessed by the Investigator. * Active severe substance abuse as assessed by the investigator in accordance with DSM-5 Substance Abuse Disorder criteria, an AUDIT score \> 15, or partial Brief Addiction Monitor (BAM) indicating the presence of illicit substance use other than cannabis (\< 3 times weekly). * They are currently undergoing another form of treatment other than supportive therapy (\> 2 times per month). * Engaged in active trauma-focused therapy including Cognitive Processing Therapy (CPT)Prolonged Exposure (PE), or Eye Movement Desensitization and Reprocessing (EMDR). * Any other condition/situation that the Investigator believes may interfere with participant safety, study conduct, or interpretation of study data.

Design outcomes

Primary

MeasureTime frameDescription
Patient satisfaction as assessed by the Client Satisfaction Questionnaire (8-item; CSQ-8)4-6 weeks(mid treatment)The CSQ-8 is an 8-item measurement of global satisfaction. The range of possible scores is 8-32; higher scores indicate higher satisfaction with treatment. Items are measured on a 4-point Likert scale where 1 indicates low satisfaction with care (e.g., quite dissatisfied, poor) and 4 indicates high satisfaction with care (e.g., very satisfied, excellent).
Satisfaction with care as assessed by the Client Satisfaction Questionnaire-8 item ( CSQ-8)8 weeks after baselineThis is an 8 item questionnaire , each is scored on a 4-point Likert scale where 1 indicates low satisfaction with care (e.g., quite dissatisfied,poor) and 4 indicates high satisfaction with care (e.g., very satisfied, excellent). for a score range of 8-32, higher score indicating better outcome
Satisfaction with care as assessed by the Client Satisfaction Questionnaire (8-item; CSQ-8)end of study (about 11-14 weeks after baseline)This is an 8 item questionnaire , each is scored on a 4-point Likert scale where 1 indicates low satisfaction with care (e.g., quite dissatisfied,poor) and 4 indicates high satisfaction with care (e.g., very satisfied, excellent). for a score range of 8-32, higher score indicating better outcome
Change in average heart rate as assessed by the emWave Inner Balance personal biofeedback device by HeartMathBaseline , 4-6 weeks(mid treatment), end of treatment (11-14 weeks)Heart rate is measured in beats per minute
Change in average coherence(heart rate variability) as assessed by the emWave Inner Balance personal biofeedback device by HeartMathBaseline , 4-6 weeks(mid treatment), end of treatment (11-14 weeks)Heart rate variability is measured via a mathematical algorithm called coherence
Change in achievement score as assessed by the emWave Inner Balance personal biofeedback device by HeartMathBaseline , 4-6 weeks(mid treatment), end of treatment (11-14 weeks)Achievement is measured via mathematical equation that includes coherence and heart rate variability and beats per minute over time. Higher achievement is associated with higher coherence sustained over time.
Reduced symptoms of PTSD as assessed by the Posttraumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (PCL-5)end of study (about 11-14 weeks after baseline)This is a 20 item questionnaire , each is scored from 0(not at all) -4( extremely)for a maximum score of 80, higher score indicating worse outcome
Increasing resilience as assessed by The Connor-Davidson Resilience Scale-10 (CD-RISC-10)4end of study (about 11-14 weeks after baseline)This is a 10 item questionnaire , each is scored from 0(not true at all) to 4(true nearly all the time) for a maximum score of 40, higher score indicating better outcome
Satisfaction with care as assessed by the Client Satisfaction Questionnaire-8-item (CSQ-8)4 weeks after baselineThis is an 8 item questionnaire , each is scored on a 4-point Likert scale where 1 indicates low satisfaction with care (e.g., quite dissatisfied,poor) and 4 indicates high satisfaction with care (e.g., very satisfied, excellent). for a score range of 8-32, higher score indicating better outcome

Secondary

MeasureTime frameDescription
Change in severity of depression as assessed by the Patient Health Questionnaire (PHQ-9)Baseline , 4-6 weeks(mid treatment), end of treatment (11-14 weeks)9 item questionnaire and each is scored from 0(not at all) to 3(nearly every day) for a maximum score of 27, higher score indicating worse outcome
Change in pain interference as assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS)-Pain Interference scaleBaseline , 4-6 weeks(mid treatment), end of treatment (11-14 weeks)This is a 6 item questionnaire and each is scored from 1(not at all) to 5(very much) for a maximum score of 30, higher score indicating more pain interference
Change in pain intensity as assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS)-Pain Intensity scaleBaseline , 4-6 weeks(mid treatment), end of treatment (11-14 weeks)This is a 3 item questionnaire and each is scored from 1(had no pain) to 5(severe pain) for a maximum score of 15, higher score indicating more pain
Change in adaptability to stress as assessed by the Situational Adaptation to Stress Scale (SASS-HSR)Baseline , 4-6 weeks(mid treatment), end of treatment (11-14 weeks)This is an 18 item questionnaire and each is scored from 1( totally disagree) to 5 (agree) for a maximum score of 90, higher score indicating better outcome
Change in difficulty to fall sleep as assessed by the Insomnia Severity Index (ISI)Baseline , 4-6 weeks(mid treatment), end of treatment (11-14 weeks)This is a 7 item questionnaire, with a score range from 0-28, higher score indicating more insomnia

Countries

United States

Contacts

Primary ContactSarah Jackson, PhD
Sarah.E.Jackson@uth.tmc.edu(281) 825-9923

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026